Skip to content

Study · Not a test of the peptide alone · 1985

2 results

[Limitation of disorders of the contractile function of the nonischemic areas of the myocardium during infarct by using the delta-sleep peptide and its cyclic derivative].

Meerson FZ, Zaiats VI, Pshennikova MG, Bozhko AP

Kardiologiia1 May 1985

PMID3839544 (opens in a new tab)PepBankPUB-03839544
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Delta sleep-inducing peptide (DSIP).

  1. 01AnimalNot a test of Delta sleep-inducing peptide (DSIP) aloneAnimal study (in vivo)Efficacy outcome

    In rats with left-ventricular infarction, pretreatment with delta-sleep peptide and its cyclic analogue significantly limited the infarct-related depression of atrial distensibility.

    In plain wordsIn rats with induced heart attack, pretreatment with delta-sleep peptide and its cyclic analogue limited the loss of atrial stretchability.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    DecreaseInfarct-related depression of right-atrial distensibility
    Study

    ratn: not reported in source

    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    These peptides, administered in a 20 micrograms/kg dose, 1 hour before the induction of experimental infarction, significantly limited the infarct-related depression of atrial distensibility and contractility
    1 context sentence
    Summary · context
    The effect of pretreatment with delta-sleep peptide (DSP) and its cyclic analogue (cDSP) on right-atrial myocardial distensibility and contractility disturbances in left-ventricular infarction (according to Selye) was studied in Wistar rats.

    In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).

  2. 02AnimalNot a test of Delta sleep-inducing peptide (DSIP) aloneAnimal study (in vivo)Efficacy outcome

    In rats with left-ventricular infarction, pretreatment with delta-sleep peptide and its cyclic analogue significantly limited the infarct-related depression of atrial contractility.

    In plain wordsIn rats with induced heart attack, pretreatment with delta-sleep peptide and its cyclic analogue limited the loss of atrial contraction strength.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    DecreaseInfarct-related depression of right-atrial contractility
    Study

    ratn: not reported in source

    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    These peptides, administered in a 20 micrograms/kg dose, 1 hour before the induction of experimental infarction, significantly limited the infarct-related depression of atrial distensibility and contractility
    1 context sentence
    Summary · context
    The effect of pretreatment with delta-sleep peptide (DSP) and its cyclic analogue (cDSP) on right-atrial myocardial distensibility and contractility disturbances in left-ventricular infarction (according to Selye) was studied in Wistar rats.

    In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.